APOE and Alzheimer disease: In the AD-ApoE Sendai and AD-ApoE Kyoto groups, human ApoE was detected on the 2nd day; reached the peak levels of 22.2 μg/mL and 17.4 μg/mL, respectively, after 4–6 days; and declined to the baseline level on the 10th day.